Skip to main content
KoBioLabs, Inc. logo

KoBioLabs, Inc. — Investor Relations & Filings

Ticker · 348150 ISIN · KR7348150004 KO Manufacturing
Open in API
Filings indexed 174 across all filing types
Latest filing 2020-11-20 Major Shareholding Noti…
Country KR South Korea
Listing KO 348150

About KoBioLabs, Inc.

http://kobiolabs.com/en/

KoBioLabs, Inc. is a biotechnology company that develops innovative microbiome-based therapeutics. The company utilizes its proprietary Smartiome® platform, an integrated system for discovering novel drug candidates that employs AI-driven multi-omics analysis and a comprehensive microbiome library with a reverse-translation approach. KoBioLabs is focused on creating a pipeline of new drugs to treat a range of immune, metabolic, and brain disorders. The company also applies advanced technologies, including a microbe-based drug delivery system (mDDS) and biofoundry techniques, to enhance the efficacy of its treatments and address unmet medical needs.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition and disposal of shares by CKD Venture Capital and its related entities in the company 'Gobio Lab'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2020-11-20 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. It details the final results of a public offering, including subscription and allocation status, shareholding changes, and the use of proceeds. This type of filing is a standard regulatory requirement following a capital raise (IPO or secondary offering) and falls under the category of share issuance and capital changes.
2020-11-12 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement) for Kobiolabs, which is a formal regulatory filing required for public offerings in South Korea. It contains detailed information about the offering, including the number of shares, pricing, underwriting details, and risk factors. It is a comprehensive document (over 180,000 characters) rather than a short announcement, and it specifically details the correction of offering terms ('정정신고서'). Given the nature of the document as a formal regulatory filing for a securities offering, it falls under the 'Regulatory Filings' category.
2020-11-06 Korean
[기재정정]투자설명서
M&A Activity Classification · 95% confidence The document is a 'Correction Report' (정정신고서) for an 'Investment Prospectus' (투자설명서) filed by GoBioLab. It details amendments to the offering price, total offering amount, and share quantities following the finalization of the public offering price. This is a formal regulatory filing related to a securities offering, which falls under the category of Proxy Solicitation & Information Statement (PSI) or Regulatory Filings (RNS). Given the specific nature of the document as a formal amendment to a prospectus for a public offering, it is best classified as a Regulatory Filing.
2020-11-06 Korean
투자설명서
Investor Presentation Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) for GoBioLab, detailing the issuance of 2,400,000 common shares. It includes sections on investment risks, business descriptions, and regulatory disclosures required for a public offering. This is a formal regulatory document filed with the Financial Supervisory Service (DART) in South Korea, which falls under the category of a prospectus for a share offering.
2020-11-03 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 100% confidence The document is a 'Correction Report' (정정신고서) for a 'Securities Registration Statement' (증권신고서) filed by GoBioLab. It explicitly details amendments to the initial registration statement, including changes to the public offering schedule, demand forecasting dates, and other procedural details related to a stock issuance. This falls under the category of capital and financing updates as it pertains to the registration and modification of securities offerings.
2020-10-12 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.